BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017

Mar 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-03-16

Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-16	Common Stock	M	23955	$3.78	Acquired	141268	Direct
2017-03-16	Common Stock	M	12500	$1.42	Acquired	153768	Direct
2017-03-16	Common Stock	F	12308	$8.80	Disposed	141460	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-16	Emp. Stock Option (Right to Buy)	$3.78	M	23955	Disposed	2021-07-01	Common Stock (23955)	Direct
2017-03-16	Emp. Stock Option (Right to Buy)	$1.42	M	12500	Disposed	2023-01-01	Common Stock (12500)	Direct

Footnotes

F1: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.